Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients

Pharmacogenomics

Volumn 12, Issue 11, 2011, Pages 1505-1508

  Zhu, Huaijun ^a   Ge, Weihong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

calcineurin inhibitor; epigenetics; orphan nuclear receptor; pharmacogenomics; renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CONSTITUTIVE ANDROSTANE RECEPTOR; CYCLOSPORIN A; CYTOCHROME P450 3A5; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; INTERLEUKIN 2; ORPHAN NUCLEAR RECEPTOR; PREGNANE X RECEPTOR;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DNA POLYMORPHISM; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; EPIGENETICS; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LONG TERM CARE; PHARMACODYNAMICS; PHARMACOGENOMICS; PROTEIN TRANSPORT; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

BIOMARKERS, PHARMACOLOGICAL; CALCINEURIN; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; ORPHAN NUCLEAR RECEPTORS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 80455158342     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.129     Document Type: Review

References (20)

1. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med. 342(9), 605-612 (2000).
2. Sommerer C, Giese T, Meuer S, Zeier M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol. Dial. Transplant. 24(1), 21-27 (2009).
3. Van Rossum HH, Press RR, den Hartigh J, de Fijter JW. Point: a call for advanced pharmacokinetic and pharmacodynamic monitoring to guide calcineurin inhibitor dosing in renal transplant recipients. Clin. Chem. 56(5), 732-735 (2010).
4. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet. 49(3), 141-175 (2010).
5. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet. Genomics. 20(9), 525-531 (2010).
6. Hirota T, Ieiri I, Takane H et al. Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status. Hum. Mol. Genet. 13(23), 2959-2969 (2004).
7. Vicari-Christensen M, Repper S, Basile S, Young D. Tacrolimus: review of pharmacokinetics, pharmacodynamics, and pharmacogenetics to facilitate practitioners understanding and offer strategies for educating patients and promoting adherence. Prog. Transplant. 19(3), 277-284 (2009).
8. Van Rossum HH, de Fijter JW, van Pelt J. Pharmacodynamic monitoring of calcineurin inhibition therapy: principles, performance, and perspectives. Ther. Drug Monit. 32(1), 3-10 (2010).
9. Sommerer C, Zeier M, Meuer S, Giese T. Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 89(11), 1417-1423 (2010).
10. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 85(1), 15-21 (2008).
11. Press RR, de Fijter JW, Guchelaar HJ. Individualizing calcineurin inhibitor therapy in renal transplantation-current limitations and perspectives. Curr. Pharm. Des. 16(2), 176-186 (2010).
12. Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J. Clin. Pharmacol. 47(5), 566-578 (2007).
13. Westlind-Johnsson A, Malmebo S, Johansson A. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos. 31(6), 755-761 (2003).
14. Benkali K, Prémaud A, Picard N et al. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48(12), 805-816 (2009).
15. Peedicayil J. Pharmacoepigenetics and pharmacoepigenomics. Pharmacogenomics 9(12), 1785-1786 (2008).
16. Dannenberg LO, Edenberg HJ. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics 7, 181 (2006).
17. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. 37(10), 2112-2117 (2009).
18. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283(15), 9674-9680 (2008).
19. Ostenfeld MS, Bramsen JB, Lamy P et al. miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene 29(7), 1073-1084 (2010).
20. Asirvatham AJ, Gregorie CJ, Hu Z, Magner WJ, Tomasi TB. MicroRNA targets in immune genes and the Dicer/Argonaute and ARE machinery components. Mol. Immunol. 45(7), 1995-2006 (2008).